Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner
Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate, securing itself a shot at challenging Merck & Co. for the opportunity.
Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate, securing itself a shot at challenging Merck & Co. for the opportunity.
